Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects With Primary Biliary Cholangitis
Conditions
Interventions
Saroglitazar Magnesium 1 mg
Saroglitazar Magnesium 2 mg
+1 more
Locations
57
United States
Zydus US007
Birmingham, Alabama, United States
Zydus US021
Tucson, Arizona, United States
Zydus US013
Los Angeles, California, United States
Zydus US011
Pasadena, California, United States
Zydus US043
Sacramento, California, United States
Zydus US022
Aurora, Colorado, United States
Start Date
April 1, 2022
Primary Completion Date
April 30, 2025
Completion Date
May 7, 2025
Last Updated
June 15, 2025
NCT07304843
NCT07449793
NCT06755541
NCT05749822
NCT05751967
NCT07296458
Lead Sponsor
Zydus Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions